Suppression of systemic autoimmunity by the innate immune adaptor STING

Shrutie Sharma  
*University of Massachusetts Medical School*

*Et al.*

---

**Let us know how access to this document benefits you.**

Follow this and additional works at: [https://escholarship.umassmed.edu/gsbs_sp](https://escholarship.umassmed.edu/gsbs_sp)

Part of the Immune System Diseases Commons, Immunity Commons, and the Skin and Connective Tissue Diseases Commons

---

**Repository Citation**

---

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Morningside Graduate School of Biomedical Sciences Student Publications by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Suppression of systemic autoimmunity by the innate immune adaptor STING

Shruti Sharmaa, Allison M. Campbellb,1, Jennie Chanb,1, Stefan A. Schattgenb,1, Gregory M. Orlowskic,1, Ribhu Nayarb, Annie H. Huylerb, Kerstin Nündelc, Chandra Mohanc, Leslie J. Bergc, Mark J. Shlomchikd,1,1, Ann Marshak-Rothsteind,1,2,3, and Katherine A. Fitzgeralda,2,3

*Program in Innate Immunity, Division of Infectious Diseases, 1Department of Pathology, and 2Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605; 3Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06519; 4Department of Immunology and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390; 5Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261; and 6Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7489 Trondheim, Norway

Edited by Ruslan Medzhitov, Yale University School of Medicine, New Haven, CT, and approved January 7, 2015 (received for review October 23, 2014)

Cytosolic DNA-sensing pathways that signal via Stimulator of interferon genes (STING) mediate immune to pathogens and also promote autoimmune pathology in DNase-I- and DNase-II-deficient mice. In contrast, we report here that STING potently suppresses inflammation in a model of systemic lupus erythematosus (SLE). Lymphoid hypertrophy, autoantibody production, serum cytokine levels, and other indicators of immune activation were markedly increased in STING-deficient autoimmune-prone mice compared with STING-sufficient littermates. As a result, STING-deficient autoimmune-prone mice had significantly shorter lifespans than controls. Importantly, Toll-like receptor (TLR)-dependent systemic inflammation during 2,6,10,14-tetramethylpentadecane (TMPD)-mediated peritonitis was similarly aggravated in STING-deficient mice. Mechanistically, STING-deficient macrophages failed to express negative regulators of immune activation and thus were hyperresponsive to TLR ligands, producing abnormally high levels of proinflammatory cytokines. This hyperreactivity corresponds to dramatically elevated numbers of inflammatory macrophages and granulocytes in vivo. Collectively these findings reveal an unexpected negative regulatory role for STING, having important implications for STING-directed therapies.

Significance

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that presents with a diverse array of clinical symptoms and afflicts over 1.5 million Americans. Current treatments involve immunosuppressive regimens associated with debilitating and adverse effects. With the description of a role for innate signaling in SLE, safe and efficient therapies that block Toll-like receptors also have been stymied by the relative short in vivo half lives of known inhibitors and the dangerous outcome of complete MyD88 blockade. Key natural regulators of the disease process are not well described but are more likely to provide disease-specific therapeutics with fewer adverse effects. In this study, we have identified a novel function for Stimulator of interferon genes as a suppressor of disease and a target for future SLE therapeutics.
mice that were Fas<sup>−/−</sup> homozygotes and either STING<sup>−/−</sup> or IRF3<sup>−/−</sup> (hereafter referred to as “STING/lpr” and “IRF3/lpr,” respectively) as well as Fas<sup>−/−</sup>IRF3<sup>−/−</sup> STING<sup>WT/WT</sup> or IRF3<sup>WT/WT</sup> (referred to as “WT/lpr”). MRL.Fas<sup>−/−</sup> mice routinely develop clinical features of SLE associated with lymphoid hypertrophy by 20–24 wk of age. However, by 16 wk of age the STING/lpr offspring displayed markedly greater splenomegaly and lymphadenopathy and higher splenocyte numbers than their STING-sufficient WT/lpr littermates (Fig. 1 A and B). Fas<sup>−/−</sup>IRF3<sup>−/−</sup> STING<sup>−/−</sup> (Het) littermates resembled the WT/lpr cohort. In contrast, the IRF3/lpr mice did not show any alteration in disease progression compared with control WT/lpr mice, and the splenic compartments were identical in composition and size (Fig. 1 A and B). Moreover, the frequency and total number of the unusual CD4/CD8 double-negative (DN) TCR<sup>B</sup> T-cell subset, characteristic of Fas<sup>−/−</sup>IRF3<sup>−/−</sup> mice (10), was increased significantly in the STING/lpr mice (Fig. 1C and Fig. S1B). STING/lpr mice also had larger numbers of total and activated CD44<sup>+</sup> CD69<sup>+</sup> B220<sup>−</sup> T cells and TCR<sup>B</sup> B cells (Fig. 1D and Fig. S1C). IRF3/lpr mice did not display any overt expansion of naive or activated T or B cells in their peripheral lymphoid organs (Fig. S1D). Importantly, STING<sup>−/−</sup> Fas-sufficient littermates (STING/WT) showed no evidence of lymphoid hypertrophy or immune activation. Additionally, the sex of the STING/lpr mice did not significantly alter the severity of disease, because both male and female STING/lpr mice showed similarly aggravated disease manifestations (Fig. S1E). Thus, STING restricts unchecked immune activation during systemic autoimmune disease and does so in an IRF3-independent manner.

**STING Deficiency Leads to Increased Autoantibody Production.** Antinuclear antibodies (ANAs) are hallmarks of SLE (11). MRL.Fas<sup>−/−</sup> mice normally make autoantibodies against both RNA- and DNA-associated autoantigens (12, 13). Importantly, STING/lpr, but not IRF3/lpr, mice had more B220<sup>+</sup> CD138<sup>+</sup> plasma cells than WT/lpr mice as well as a significantly greater incidence of IgG class-switched antibody-producing cells as determined by ELISPOT (Fig. 2A and Fig. S1F). To comprehensively compare autoantibody specificity and titers of the STING/lpr and WT/lpr mice, we used autoantigen microarrays (14). This analysis showed an overall increase in autoantibody titers in the STING/lpr sera, compared with WT/lpr littersmates, especially with regard to autoantigens commonly associated with SLE such as DNA, histones, chromatin, small nuclear ribonucleoproteins, C1q, granulocyte markers, and extracellular matrix (Fig. 2B). Notably, the reactivity of sera from the 16-wk-old STING/lpr mice was markedly elevated compared with sera from age-matched WT/lpr littersmates and more closely resembled the sera from 25-wk-old WT/lpr littersmates.

**STING Deficiency but Not IRF3 Deficiency Leads to Accelerated Mortality, Lupus Nephritis, and Gross Morbidity in the MRL.Fas<sup>−/−</sup> Model.** In agreement with their disease severity, STING/lpr mice exhibited more extensive renal disease than their WT/lpr littersmates, as determined both by proteinuria and histological examination of the kidneys at 16 wk of age (Fig. 3A and B). Histological examination of the STING/lpr kidneys showed a greater degree of monocytic and lymphocytic infiltrates (Fig. 3B, a–c), substantial protein deposition, and thickening of the basement membranes (Fig. 3B, d–f). Overall the STING/lpr mice had significantly higher nephritis scores (Fig. 3C), whereas the IRF3/lpr mice showed no signs of accelerated renal disease (Fig. 3D). Importantly, more severe nephritis was associated with significantly accelerated mortality in the STING/lpr mice. The median age at death was 17.5 wk for STING/lpr mice compared with 26 wk for the WT/lpr mice (P = 0.0037) (Fig. 3E).

**STING Deficiency but Not IRF3 Deficiency Leads to the Expansion of Unusual Inflammatory Myeloid and Dendritic Cell Populations.** Although STING is expressed ubiquitously, its expression in myeloid cells is closely tied to its role in innate responses (3, 15). Intriguingly, the number and activation status of myeloid cells (CD11b<sup>+</sup> or CD11c<sup>+</sup>) in the STING/lpr spleens was increased greatly compared with WT/lpr littersmates (Fig. 4 A and B and Fig. S2A). Within the myeloid compartment, CD11b<sup>+</sup> Ly6C<sup>hi</sup> cells are considered a highly inflammatory class of monocytes, and the Ly6C<sup>hi</sup>/Ly6C<sup>int</sup> subset consists of inflammatory neutrophils (16). Both subsets are characterized by their association with SLE disease and by their ability to express the interferon signature (17). Therefore, we were interested in understanding what might drive their expansion in STING/lpr mice. Although the expanded Ly6C<sup>hi</sup> cells had a monocytic morphology (Fig. 4C), they coexpressed activated F4/80<sup>+</sup> and the proinflammatory cytokine TNF-α (Fig. 4D).

**Fig. 1.** Lymphoid hypertrophy and increased immune activation in STING-deficient but not in IRF3-deficient autoimmune-prone mice. (A) Weights of spleens and largest axillary lymph nodes (LN) from F2 littersmates. (B) Total number of splenic cells. (C, Left) Identification of splenic TCR<sup>B</sup> T cells. (Right) Percentages of B220<sup>−</sup> TCR<sup>B</sup> cells determined by FACS analysis. (D) Percentages of activated splenic TCR<sup>B</sup> T cells (Left) and B220<sup>−</sup> B cells (Right) based on CD44 and CD69 activation markers. P values for STING/lpr vs. WT/lpr are noted (one-way ANOVA). Mice were 16 wk old unless otherwise noted.
with an inflammatory milieu and are thought to give rise to cells that participate heavily in tissue destruction and remodeling (17, 18). Notably, STING/lpr mice showed a significant expansion and activation of both Ly6C<hi> inflammatory monocyte (R1) and Ly6G<hi> neutrophil (R2) populations (Fig. 4C and Fig. S2B and C). Activated F4/80<sup>+</sup> macrophage populations were increased similarly (Fig. S2D). Importantly, neither macrophage nor neutrophil populations were altered significantly in the IRF3/lpr mice (Fig. S2E). There was also an increased frequency of F4/80<sup>+</sup> Ly6C<hi> and CD11c<sup>+</sup> inflammatory dendritic cells (IDC) (Fig. 4C and Fig. S2F). IDCs arise from the Ly6C<hi> inflammatory progenitor pools and are a major source of proinflammatory cytokines in models of tumor immunity (17, 18). The role of IDCs in SLE has not been noted or described previously, and therefore their presence in the accelerated pathology in STING/lpr was unexpected. The expansion of the Ly6CG<hi> populations correlates with increased systemic levels of neutrophil- and macrophage-derived chemo-

kines and cytokines including the M1-associated cytokines TNF-α and IL-6 and chemokines (CCL2, CCL5, CXCL1, CCL3, and CCL4) (Fig. 4D and Fig. S2G). Of note, IL-9 and IL-3 promote the proliferation and differentiation of hematopoietic stem cells into myeloid progenitor cells (19, 20), and increased systemic levels of IL-9 and IL-3 correlate directly with the myeloid expansion seen in STING/lpr mice (Fig. 4D). Together these data highlight the previously unrecognized role that STING normally plays in limiting the expansion and activity of pathogenic myeloid populations in systemic autoimmune diseases such as SLE.

**STING Deficiency Results in the Increased Expression of IFN-Stimulated Genes and IFN-α-Secreting Cell Populations.** Type I IFNs have been shown to play a significant role in SLE (21). Therefore it was essential to determine whether the IFN signature was altered in the STING/lpr mice. Gene-expression profiling of STING/lpr and WT/lpr splenocytes showed a significant increase in the expression of IFN-stimulated genes (ISGs) in STING/lpr spleens compared with WT/lpr littermates, as is consistent with disease severity but paradoxical with STING deficiency (Fig. 4E). An upregulated ISG signature generally is indicative of increased levels of type I IFNs and IFN-producing cells in the periphery. Plasmacytoid dendritic cells (pDCs) are thought to be the major type I IFN-producing cell (IPC) in both murine models of SLE and in human patients, although other myeloid and lymphoid lineage cells also are known contributors (22, 23). Importantly, the number of pDCs identified as CD11<sup>+</sup>^SSiglec-H^Bst2<sup>+</sup> (Fig. S3A) was increased significantly in the spleens from STING/lpr mice but not in the IRF3/lpr spleens (Fig. S3B). By using intracellular staining, we identified not only increased numbers of IFN-α-producing pDCs but also IFN-α-producing Ly6C<hi> and Ly6C<lo> monocytes in STING/lpr mice (Fig. 4 F and G and Fig. S3C). IFN-α–producing Ly6C<hi> monocytes have been found at the site of viral infections as well as in inflammatory diseases such as colitis (18). However, the increase in IFN-α–Ly6C<hi> cells was surprising (Fig. 4G), because these subsets have not been identified previously as sources of type I IFN in SLE or other diseases. This finding suggests that typical and atypical IFN-α–producing pathways are significantly dysregulated in the absence of STING.

**TMPD-Induced Peritonitis Is Amplified by STING Deficiency.** Several key features of SLE are recapitulated by the i.p. injection of the hydrocarbon oil TMPD (also known as “pristane”). These features include a type I IFN signature, ANAs, and glomerulonephritis (24, 25). Importantly, TMPD-induced autoimmunity is dependent upon TLR7 and type I IFNs (26). Pristane injection of C57Bl/6 mice results in an early and persistent peritoneal inflammation and the recruitment of TLR7<sup>+</sup>Ly6C<hi> monocytes, a potential source of type I IFNs, in this model (25). We thus sought to determine if TMPD-induced, TLR-dependent inflammation is also modulated by STING. The extravasation of inflammatory monocytes and granulocytes into the peritoneal cavity following TMPD administration was entirely dependent on endosomal TLRs, because no evidence of inflammation occurred in pristane-treated Unc93b<sup>−/−</sup> mice (Fig. 5A). In comparison, STING<sup>−/−</sup> mice showed greater accumulation in total cells, CD11b<sup>+</sup> myeloid cells, and especially CD11b<sup>+</sup>Ly6C<hi> inflammatory monocytes. The expression of ISGs (IRF7 and Myx1) was also increased in the peritoneal exudate cells (PECs) from STING<sup>−/−</sup> mice but not Unc93b<sup>−/−</sup> mice (Fig. 5B), again implicating type I IFN in pathology. Although there was no significant increase in the number of Ly6C<hi>Ly6G<hi> granulocytes in the peritoneum, the percentage of Ly6C<hi>Ly6G<hi> granulocytes was significantly higher in the spleens of the TMPD-injected STING<sup>−/−</sup> mice than in controls (Fig. 5C). The accumulation of inflammatory granulocytes in the spleens of pristane-treated mice at 6 mo post-injection has been reported previously (16); however, to our knowledge, this is the first report of such an early signature of
systemic inflammation. These data document a second example in which STING negatively regulates a TLR-dependent inflammatory response.

**Macrophages Derived from STING-Deficient Mice Are Hyperresponsive to TLR7 and TLR9 Ligands.** In all SLE models evaluated to date, immune activation depends on the ability of endogenous TLRs to recognize nucleic acid-associated autoantigens (25, 27). Therefore, we reasoned that STING/lpr-derived macrophages could be inherently more reactive to such autoantigens via TLR7- and/or TLR9-dependent pathways. To test this possibility directly, bone marrow-derived macrophages (BMMs) from STING/lpr and WT/lpr mice were stimulated with TLR7 and TLR9 ligands (Fig. 6 A). As expected, STING/lpr macrophages failed to produce the proinflammatory cytokines TNF-α and IL-6 in response to TLR ligands but C57BL/6 BMMs (Fig. S3B). In addition, we also compared STING-deficient and STING-sufficient genes, we also compared STING-deficient and STING-sufficient, IRF3+/-/lpr and IRF3+/+/lpr splenic tissue also revealed a significant increase in the expression of these negative regulators (Fig. 6G). To confirm that the expression of these negative regulators was regulated directly by STING, we determined the effect of STING overexpression on these genes. We found that stable overexpression of STING+/-/lpr BMMs resulted in elevated levels of IFN-α and IL-6 in response to TLR ligands but not in response to cytosolic DNA ligands (Fig. S3D).

Secreted negative regulators of immune responses also contribute to self-tolerance. Recent studies have shown that myeloid cell production of Indoleamine 2,3-deoxygenase-1 (IDO-1), particularly by dendritic cells (DCs), promotes the conversion and expansion of regulatory T cells (28). When spleen sections from 16-wk-old STING/lpr and WT/lpr littermates were stained with an antibody against IDO-1, we observed a marked increase in the number of cells expressing IDO-1 in the spleen of STING/lpr mice compared with WT/lpr mice (Fig. 6H). These findings suggest that STING deficiency results in the increased expression of IDO-1, which may contribute to the self-tolerance observed in STING/lpr mice.

**STING Deficiency but Not IRF3 Deficiency Results in Reduced Levels of Known Negative Regulators of TLR Signaling.** STING deficiency could lead to amplified activation of TLR-dependent macrophage responses either by increasing the level of TLR expression or by decreasing negative regulation of TLR signaling. We compared basal levels of endosomal TLRs in WT, STING+/−, WT/lpr, and STING/lpr BMMs but found no difference in TLR3, TLR7, or TLR9 expression (Fig. S5A). Surprisingly, unstimulated STING+/− BMMs had dramatically decreased expression of several well-characterized negative regulators of TLR signaling, including A20 and suppressor of cytokine signaling 1 (SOCS1) and 3 (SOCS3), compared with WT controls (Fig. 6 C and D). Importantly, these genes are not regulated through an IRF3-dependent mechanism, because IRF3+/− BMMs did not display any change in basal expression levels of these critical negative regulators (Fig. 6C). Levels of A20, SOCS1, and SOCS3 were also decreased substantially in activated STING+/− BMMs (Fig. S5B). Similar analysis of STING/lpr- and WT/lpr-derived BMMs revealed significantly attenuated A20, SOCS1, and SOCS3 levels basally and in response to TLR ligands (Fig. 6E and Fig. S5C). Furthermore, gene profiling of STING/lpr and WT/lpr splenic tissue also revealed a significant decrease in the expression of these negative regulators (Fig. 6E). To confirm that the expression of these negative regulators was regulated directly by STING, we determined the effect of STING overexpression on these genes. We found that stable overexpression of STING in RAW264.7 macrophage cells resulted in elevated basal levels of A20, SOCS1, and SOCS3 levels as well as in response to TLR ligands (Fig. 6F). Moreover, ectopic expression of STING reduced the production of TNF-α and IL-6 in response to TLR ligands but not in response to cytosolic DNA ligands (Fig. S5D).
with anti-IDO-1 antibody, spleens from STING/lpr mice had greatly reduced IDO-1 levels compared with age-matched littermate controls (Fig. 6G). Because IDO-1 is thought to control the generation of Treg cells, we determined the number of Treg cells in STING/lpr and control mice. We found that STING/lpr mice had significantly lowered percentages of activated CD4+ CD25+ Foxp3+ Treg cells and also tended toward lowered percentages of CD4+ Foxp3+ Treg cells in axillary lymph nodes (Fig. 6H). These data, along with other recent studies (29), explain how immune suppression in STIFT/-/- animals may be systemically compromised. Overall, these data strongly indicate that in the context of an SLE autoimmune-prone background, STING-deficient myeloid cells mount an amplified response to nucleic acid-associated autoantigens caused by the reduced expression of molecules that directly or indirectly limit immune activation.

**Discussion**

Foreign DNA can trigger both endosomal TLR9 and cytosolic STING-dependent DNA sensors, leading to the robust production of type I IFNs and other proinflammatory cytokines important in the clearance of microbial pathogens. Chronic stimulation of these sensors by endogenous ligands also provokes debilitating auto-inflammatory or autoimmune diseases such as seen in mice or humans with compromised capacities to degrade DNA. In contrast to experimental settings where STING provokes inflammation, our studies show that STING can attenuate inflammation in both a chronic systemic autoimmune disease and in an acute inflammatory response that is dependent on TLR-mediated detection of endogenous ligands. STING-deficient MRL/lpr mice develop a dramatically accelerated disease profile characterized by the expansion and activation of both the lymphoid and myeloid compartments, increased numbers of type I IFN-producing cells, elevated autoantibody titers, and a shorter lifespan. Similar to our findings in the MRL/lpr model, STING deficiency exacerbated TMPD-induced inflammation, a condition also associated with type I IFNs and TLR-activated Ly6C+ monocytes (24, 26).

Nonautoimmune-prone STING-deficient mice do not exhibit any evidence of systemic autoimmunity. Therefore, the exacerbated disease phenotype of the STING-deficient MRL/lpr mice likely results from the failure to constrain aberrantly activated TLR signaling cascades responsible for disease. Intriguingly, A20-, SOCS1-, or SOCS3-deficient mice exhibit phenotypes similar to our STING/lpr mice (30, 31). In addition to impaired expression
of these negative regulators of TLR activation, STING/lpr mice also failed to express the secreted immunosuppressive protein IDO-1. Previous studies documented IDO-1 expression in the spleens of prediseased MRL.FasPpr mice and its reduced expression with disease progression (32). Moreover, treatment with an IDO-1 inhibitor 1-methyl tryptophan (1-MT) accelerates disease in the MRL.FasPpr mice, implicating IDO-1 in the negative regulation of immune activation associated with autoimmunity. Because IDO-1 is potently induced by TLR-dependent and -independent pathways and regulates the expansion of Tregs, it is a critical factor in limiting disease severity (28). Recently, Huang et al. (33) showed that IDO-1 expression in DCs is attenuated in the absence of STING, leading to increased IL-6 production by STING\textsuperscript{−/−} DCs in response to apoptotic cells. We now show decreased IDO-1 levels and a corresponding decrease in Treg cells in STING-deficient SLE-prone mice. These conditions are likely to contribute to the exacerbated disease phenotype.

A seemingly unrelated outcome of disease in the STING/lpr mice is the large number of monocytic cells in secondary lymphoid tissues. However, monocye egress from the bone marrow and local proliferation is a known consequence of TLR engagement (34). Whether increased TLR activity also contributes to the excess production of the hematopoiesis-modulating cytokines IL-9 and IL-3, thereby further promoting myeloid expansion in STING/lpr animals, remains to be determined.

Although an increase in proinflammatory cytokines in response to apoptotic cells and TLR9 and TLR3 ligands has been noted previously in STING\textsuperscript{−/−} macrophages by other investigators (33, 35), the significance of this dysregulation of TLR signaling was not addressed further or extended to other TLRs. Previous studies have focused largely on the ability of STING to engage the TBK1–IRF3 signaling pathway. It is critical to note that, thus far, IRF3 has been implicated only in the transcription of type I IFNs (36). Furthermore, IRF3 deficiency does not affect the disease course of MRL/lpr, and therefore it is likely that a STING-dependent but IRF3-independent pathway mediates the effects we observed. Intriguingly, some evidence exists for the role of IRF3/7 heterodimers in inducing type I IFNs downstream of STING (37). However, a definitive role for IRF7 has not yet been evaluated in lupus and may contribute to lupus pathology downstream of both STING and TLRs. Prior studies have shown that cytosolic DNA can induce the expression of proinflammatory cytokines through the activation of an NF-κB-dependent pathway downstream of STING (3). Intriguingly, we show that the basal expression of negative regulators of TLR signaling such as A20, SOCS1, and SOCS3, known NF-κB target genes, is down-regulated significantly in STING\textsuperscript{−/−} cells but not in IRF3\textsuperscript{−/−} cells. These data further highlight the contribution of NF-κB signaling downstream of STING under homeostatic conditions and point to a constitutive role of this pathway in immune regulation. It is possible that other transcription factors, such as IRFs and STATs, may be engaged downstream of STING, but likely candidates IRF5, IRF1, STAT1, and STAT6 have previously been shown to promote lupus pathology (38–42), in contrast to the suppressive role of STING documented in this study. Thus, it is unlikely that transcriptional activity of any of these factors contributes to a STING-dependent suppressive pathway.

Dysregulation of TLR signaling is a recurrent theme in the development and severity of systemic autoimmune diseases such as SLE. Both TLR7 and TLR9 activation have been linked to the pathogenesis of SLE (43). However, despite similar tissue expression and signaling pathways, deficiency of these TLRs on MRL.FasPpr background, as well as other autoimmune-prone strains, has revealed opposing roles for these TLRs in SLE. Although opposing roles of TLR7/9 in autoimmunity have been known for some time, mechanistic insight into their cross-regulation is still lacking. In many ways the exacerbated disease we observed in STING/lpr mice resembles that reported for TLR9/lpr mice: both strains show elevated expression of ISGs and marked expansion and activation of lymphocyte compartments. Our studies now suggest that modulation of negative regulators of signaling may be a common mechanism of cross-regulation applicable to TLRs as well as other innate pathways during autoimmune.

It is conceivable that the negative regulatory role of STING we observed is independent of its role in DNA sensing and...
represents a homeostatic role for STING resulting from stochastic dimerization. Alternatively, low levels of cytosolic DNA, perhaps through reactivated retro-elements, may account for the homeostatic involvement of STING. The precise mechanism by which STING regulates homeostasis remains an open question. Perhaps through reactivated retro-elements, may account for the homeostatic involvement of STING.

**Fig. 6.** STING regulates responsiveness to TLR ligands and controls the expression of critical negative regulators of innate signaling. (A) Levels of TNF-α and IL-6 secreted by BMMs from WT/lpr, STING/lpr, WT/WT, and STING/WT mice in response to TLR9 (CpGB, 5 μM), TLR7 (CLO97, 300 ng/mL), and ISD (3 μM) ligands. Supernatants were collected 24 h after stimulation. (B) Levels of IL-6 from C57BL/6 and STING−/− BMMs treated with a range of concentrations of CpGB (TLR9) and CLO97 (TLR7) for 24 h. Concentrations and units are noted. (C) Nanostring mRNA profiling of key negative regulators of innate signaling in BMMs derived from C57BL/6, STING−/−, and IRF3−/− mice after stimulation with ISD for 3 h, represented as a heatmap. The analysis compares the mean intensities of gene expression in C57BL/6, STING−/−, and IRF3−/− BMMs and is transformed by a log2 function. (D) Real-time PCR analysis of A20, SOCS1, and SOCS3 mRNA from unstimulated C57BL/6 (black bars) and STING−/− (gray bars) BMMs. (E, Left) Real-time PCR analysis of A20, SOCS1, and SOCS3 mRNA in WT/lpr mice (47) were crossed to Fas-deficient, lupus-prone MRL/Flpr (gray bars) mice. (H) Percentages of CD25+ Foxp3+ and total Foxp3+ (Treg cells) T cells gated on live CD4+ T cells from the axillary lymph node of WT/lpr and STING/lpr mice. P values in A–E were calculated using Student’s t test; P values in G were calculated using two-way ANOVA.

**Experimental Procedures**

**Generation and Characterization of Autoimmune STING-Deficient Mice.** The University of Massachusetts Medical School and Yale Institutional Animal Care and Use Committees approved all animal work.

STING−/− mice (3) (from G. Barber, University of Miami, Coral Gables, FL) and IRF3−/− mice (47) were crossed to Fas-deficient, lupus-prone MRL/Mp–lpr/lpr mice (Jackson Laboratory). A controlled F2 intercross between heterozygote STING+/−/lpr−/− littermates was used to generate STING-deficient lupus-prone mice homozygous for deficiency in Fas as well as STING (STING/lpr, n = 17–20) or wild type for STING (WT/lpr, n = 9–15). The heterogeneous genetic composition of the F2 generation was controlled by the use of large cohorts of littermates. Most mice were analyzed at 16 wk of age; three STING/lpr mice and three WT/lpr mice were analyzed at 25 wk of age.
Experiments are reported as the means ± SEM. Statistical comparisons were made using a Student t test and GraphPad Prism software (GraphPad Software) for bivariate studies and one-way ANOVA for multivariate studies. P values for all criteria measured are reported, and P values <0.05 were considered statistically significant.

Please see SI Experimental Procedures for more information on the methods used in this study.

37. Sharma S, et al. (2011) Innate immune recognition of an AT-rich stem-loop DNA motif provided by NIH Grant 2T32GM07205. Support for J.C., S.A.S., and G.M.O. was provided by NIH Grant 5T32AI095213.